You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 147 No. 6, June 1987 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Need for Insulin Therapy in Type II Diabetes Mellitus

A Randomized Trial

Linda M. Frazier, MD; Cynthia D. Mulrow, MD; Lovest T. Alexander, Jr, PA-C; Robert T. Harris, MD; Kathleen R. Heise, RD; J. Trig Brown, MD; John R. Feussner, MD

Arch Intern Med. 1987;147(6):1085-1089.


Abstract



• To identify patients with type II diabetes mellitus for whom insulin therapy is most beneficial, we conducted a randomized controlled trial in the general medicine clinic of a university hospital. Asymptomatic, obese, insulin-treated patients were given diet and diabetes education and, in half of these patients, insulin therapy was withdrawn. Over six months, patients developing hyperglycemic symptoms or acetonemia were counted as study failures. Failure criteria developed in 13 of 25 insulin-withdrawal patients, at a median of four weeks after withdrawal, compared with two of 24 control subjects. Elevated stimulated glucose levels predicted the need for insulin therapy. Hyperglycemia worsened in insulin-withdrawal patients who did not meet study failure criteria, but it improved in control patients. Study patients were insulin deficient as shown by low baseline C peptide values (0.43±0.05 nmol/L). The prompt metabolic decompensation precipitated by insulin withdrawal suggests that insulin-deficient patients may benefit from insulin therapy and may need it to prevent symptomatic hyperglycemia.

(Arch Intern Med 1987;147:1085-1089)



Author Affiliations



From the Division of General Internal Medicine (Drs Frazier, Mulrow, Harris, Brown, and Feussner and Mr Alexander) and the Department of Dietary Services (Ms Heise), Duke University, Durham, NC; and the Health Services Research Field Program, Durham (NC) Veterans Administration Medical Center (Dr Feussner). Dr Mulrow is currently at the University of Texas at San Antonio.


Footnotes



Accepted for publication Nov 18, 1986.

Read before the national meeting for the Society for Research and Education for Primary Care Internal Medicine, Washington, DC, May 2, 1985.

Reprint requests to the Division of General Internal Medicine, Box 3293, Duke University Medical Center, Durham, NC 27710 (Dr Frazier).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt and Hirsch
JAMA 2003;289:2254-2264.
ABSTRACT | FULL TEXT  

Insulin Pharmacotherapy
Datt
Clin-Alert 1973;11:260-270.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.